Haemonetics (HAE) Aktievy
Haemonetics Corporation är ett medicintekniskt företag som tillhandahåller en rad lösningar för sjukhusteknik. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
HAE Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Haemonetics Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$108.22 |
| 52 veckors högsta | US$109.56 |
| 52 veckors lägsta | US$47.32 |
| Beta | 0.52 |
| 1 månads förändring | 38.62% |
| 3 månaders förändring | 65.25% |
| 1 års förändring | 100.48% |
| 3 års förändring | 25.23% |
| 5 års förändring | 81.88% |
| Förändring sedan börsintroduktionen | 1,722.65% |
Senaste nyheter och uppdateringar
Seeking Alpha • 1h
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Summary Haemonetics is a medtech company that’s increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential. Lastly, I think HAE’s valuation still looks reasonable despite the impressive rally during 2026. So, while I reckon there’s less margin of safety today, HAE still looks compelling as a speculative “Buy” for long-term investors. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 12
HAE: FY27 Execution And Vascular Closure Advances Will Shape Rerating Potential
Haemonetics' analyst fair value estimate has increased by $10 to $96.90 as analysts respond to a series of higher price targets tied to Q1 beat and raise results, expectations for stronger FY27 performance, and ongoing optimism around profitability and debt reduction. Analyst Commentary Recent research on Haemonetics points to a broadly constructive view on the stock, with several bullish analysts lifting price targets following Q1 results and updated outlooks.Recent updates
Seeking Alpha • 1h
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Summary Haemonetics is a medtech company that’s increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential. Lastly, I think HAE’s valuation still looks reasonable despite the impressive rally during 2026. So, while I reckon there’s less margin of safety today, HAE still looks compelling as a speculative “Buy” for long-term investors. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 12
HAE: FY27 Execution And Vascular Closure Advances Will Shape Rerating Potential
Haemonetics' analyst fair value estimate has increased by $10 to $96.90 as analysts respond to a series of higher price targets tied to Q1 beat and raise results, expectations for stronger FY27 performance, and ongoing optimism around profitability and debt reduction. Analyst Commentary Recent research on Haemonetics points to a broadly constructive view on the stock, with several bullish analysts lifting price targets following Q1 results and updated outlooks.
Uppdatering av berättelse • Jul 29
HAE: Recent Index Additions And Buybacks Will Face Catalyst Fatigue Risk
Haemonetics' analyst fair value estimate has moved from $62.00 to about $65.93 as analysts factor in recent price target increases tied to perceived Plasma and Hospital upside, sector model updates, and changing expectations around near-term catalysts. Analyst Commentary Recent research on Haemonetics shows a mix of optimism around Plasma and Hospital opportunities and caution around how much good news is already reflected in the stock.Uppdatering av berättelse • Jun 24
HAE: Vascular Closure Optimism Will Face Ongoing Execution And Reporting Restructure Risk
Haemonetics enters this narrative update with a higher Street price target range, highlighted by Citi lifting its target to $70 from $64 and BofA raising its target to $80 from $72. Analysts reference updated medical technology models, a view that vascular closure may have turned a corner, and what they see as conservative guidance with potential upside across all three segments.Uppdatering av berättelse • Jun 08
HAE: Vascular Closure Optimism Will Face Growing Concerns Over Execution Risk
Haemonetics' analyst price targets have shifted higher, with recent moves from $64 to $70 and from $72 to $80, as analysts point to solid sector fundamentals, a perceived turning point in vascular closure, and what they view as more durable plasma upside. Analyst Commentary Recent Street research on Haemonetics shows a mix of supportive and cautious views.Analysartikel • May 27
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings
The market for Haemonetics Corporation's ( NYSE:HAE ) shares didn't move much after it posted weak earnings recently...Uppdatering av berättelse • May 25
HAE: Vascular Closure And Plasma Upside Will Offset Recent Cautious Repricing
Haemonetics' updated analyst price target has shifted from $64.00 to $62.00 as analysts balance slightly adjusted fair value and profitability assumptions with views that potential upside to guidance in vascular closure and plasma could prove more durable over time. Analyst Commentary Recent Street research on Haemonetics reflects a mix of optimism around vascular closure and plasma, alongside a series of lower price targets that highlight ongoing execution and growth questions.Uppdatering av berättelse • May 09
HAE: New Approvals And Trials Will Support Upside Despite Cautious Repricing
Haemonetics' updated analyst price target reflects a modest reset in expectations, with several firms trimming their targets by $4 to $12 as analysts factor in slightly lower revenue growth assumptions, a marginally higher profit margin outlook, and a small adjustment to the assumed future P/E multiple. Analyst Commentary Recent research shows a cluster of bearish adjustments to Haemonetics' price targets, with several bearish analysts trimming their numbers in close succession.Uppdatering av berättelse • Apr 22
HAE: Pipeline And Product Updates Will Offset Cautious Sector Repricing
Haemonetics' implied fair value price target has been revised to $64 from $70 as analysts factor in updated sector peer multiples, adjustments to revenue growth and margin assumptions, and a slightly higher discount rate following recent Street research updates. Analyst Commentary Recent Street research around Haemonetics reflects a more cautious tone as several bearish analysts trim their price targets and revisit their assumptions on growth, margins, and valuation risk.Uppdatering av berättelse • Apr 08
HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing
Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.Uppdatering av berättelse • Mar 25
HAE: Vivasure Deal And Pipeline Progress Will Support Future Share Recovery
Analysts have reduced the Haemonetics fair value estimate to $70 from $74. Recent target resets in the group, including Citi's move to $70, reflect updated assumptions around growth, margins and the P/E multiple for the stock.Uppdatering av berättelse • Mar 10
HAE: Vivasure Deal And 2026 Outlook Will Support Earnings Quality
Analysts have modestly adjusted their views on Haemonetics, with several firms trimming price targets by $10 to $18 and one small $1 upward revision. These changes reflect updated assumptions on valuation multiples, while fair value and key model inputs remain broadly unchanged.Uppdatering av berättelse • Feb 23
HAE: Vivasure Acquisition And FY26 Outlook Will Support Margin Recovery
The analyst price target for Haemonetics has been reduced by $3.70, with analysts pointing to a slightly higher discount rate, a lower fair value estimate and some pressure on projected profit margins, even as they continue to apply a higher forward P/E and updated revenue growth assumptions in their models. Analyst Commentary Recent Street research on Haemonetics has been mixed, with several firms trimming their price targets while at least one firm has lifted its target in connection with the Vivasure Medical acquisition.Uppdatering av berättelse • Feb 08
HAE: Vivasure Acquisition Will Drive Execution And Support Future Share Recovery
Analysts have trimmed their fair value estimate for Haemonetics to about $74.00, reflecting mixed Street price target moves that weigh recent target cuts from several firms against at least one increase tied to a favorable view of the Vivasure Medical acquisition. Analyst Commentary Recent Street research around Haemonetics reflects a split view, with several bearish analysts trimming price targets and a smaller group seeing upside tied to the Vivasure Medical acquisition.Uppdatering av berättelse • Jan 25
HAE: Vivasure Deal And Buyback Will Shape Execution And Share Recovery
Analysts have lifted their price target for Haemonetics from about $58 to roughly $74.82, citing recent Street research that points to higher assumed revenue growth, slightly stronger profit margins, a higher future P/E, and supportive views on the Vivasure acquisition and recent earnings execution. Analyst Commentary Recent Street research has centered on two main themes for Haemonetics, the Vivasure acquisition and the company’s latest earnings print.Uppdatering av berättelse • Jan 11
HAE: Achievable Hospital Reset And FY26 Outlook Will Support Gradual Recovery
Narrative Update on Haemonetics Analysts have inched up their price target for Haemonetics, with updated fair value rising from about US$90 to roughly US$92, citing recent price target increases, company performance that met or exceeded expectations across segments, and what they view as more achievable guidance and improved credibility on execution and messaging. Analyst Commentary Recent commentary has focused on how Haemonetics is executing against expectations, how realistic its guidance looks, and what that might mean for valuation support and potential growth in the medium term.Analysartikel • Jan 06
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Uppdatering av berättelse • Dec 24
HAE: Achievable Hospital Guidance Reset Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $90 from about $86, citing stronger than expected execution across all segments, a more achievable Hospital guidance reset, and an improved long term sales outlook that supports higher growth and valuation assumptions. Analyst Commentary Analysts see the recent quarter as a constructive inflection point for Haemonetics, with improved guidance and execution supporting a modestly higher valuation framework, though some caution remains around sustainability of growth and delivery against new targets.Uppdatering av berättelse • Dec 10
HAE: Broad Outperformance And Achievable Hospital Guidance Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $86 from about $85, citing broad-based outperformance, more achievable Hospital guidance, and an upgraded FY26 sales outlook that supports a gradual recovery in the shares. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the price target increase toward the high $80s reflects growing confidence in the company’s ability to sustain outperformance across all operating segments.Uppdatering av berättelse • Nov 26
HAE: Solid Execution And Achievable Guidance Will Support Measured Share Recovery
Analysts have raised their price target for Haemonetics from $83 to approximately $84.55. They cite solid execution, an improved sales outlook, and increased confidence in the company's guidance and operational credibility.Uppdatering av berättelse • Nov 12
HAE: Upbeat Execution And Reset Guidance Should Drive Share Price Recovery
Haemonetics' analyst price target has been raised from $76.27 to $83.00, as analysts cite improved execution, strong segment performance, and a more optimistic sales outlook as key drivers for the upward revision. Analyst Commentary Following recent quarterly results and the revised price target, analysts have shared both optimistic highlights and points of caution regarding Haemonetics' outlook and valuation.Analysartikel • Nov 07
A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb
Haemonetics Corporation ( NYSE:HAE ) shares have had a really impressive month, gaining 36% after a shaky period...Uppdatering av berättelse • Oct 28
Execution Challenges Will Shift Outlook For Global Plasma And Hemostasis Expansion
Haemonetics’ analyst price target has been revised lower by analysts to approximately $76 from $77. This change reflects concerns about execution within the Interventional Technologies segment, despite confidence in the company’s long-term value.Uppdatering av berättelse • Oct 14
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The analyst price target for Haemonetics has been lowered by approximately $1.73 to $76.91. Analysts cite ongoing concerns around sales execution and challenges in the Interventional Technologies segment.Analysartikel • Sep 15
Is Haemonetics Corporation (NYSE:HAE) Trading At A 48% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Haemonetics fair value estimate is US$100 Haemonetics...Uppdatering av berättelse • Aug 08
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18. What's in the News Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index Valuation Changes Summary of Valuation Changes for Haemonetics The Consensus Analyst Price Target has fallen from $92.45 to $85.18.Seeking Alpha • Feb 20
Haemonetics: Almost Blood In The Streets
Summary Haemonetics shares have been trading at more appealing levels after a reduction in full-year sales guidance, trading at historically reasonable levels. The company, generating $1.3 billion in annual sales, has seen modest growth, with significant contributions from its plasma and hospital segments. Despite a cautious outlook due to suboptimal positioning in some units, Haemonetics aims for continued growth in 2025, aided by M&A efforts. Shares have fallen to $64, valuing the business at 3 times sales, with adjusted earnings multiples dropping to mid-teens multiple. The appeal is improving here. Read the full article on Seeking Alpha
Ny berättelse • Sep 03
Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth
Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.Seeking Alpha • Jun 21
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter vascular closure, but recent M&A deals have been more questionable. Haemonetics should see revenue reacceleration in FY'26, with long-term revenue growth of 6% to 7% and margin improvement driving a fair value above $100. Read the full article on Seeking AlphaAktieägarnas avkastning
| HAE | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | 19.7% | -1.2% | -2.1% |
| 1Y | 100.5% | -12.8% | 18.8% |
Avkastning vs industri: HAE översteg US Medical Equipment branschen som gav -12.8 % under det senaste året.
Avkastning vs Marknaden: HAE översteg US marknaden som gav 18.8 % under det senaste året.
Prisvolatilitet
| HAE volatility | |
|---|---|
| HAE Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: HAE har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: HAE s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1971 | 3,009 | Chris Simon | www.haemonetics.com |
Haemonetics Corporation är ett medicintekniskt företag som tillhandahåller en rad tekniska lösningar för sjukhus. Företaget är verksamt inom segmenten Plasma, Blood Center och Hospital. Företaget tillhandahåller automatiserade system för insamling av plasma, programvara för hantering av givare och stödjande programvarulösningar, t.ex.
Haemonetics Corporation Sammanfattning av grunderna
| HAE grundläggande statistik | |
|---|---|
| Börsvärde | US$4.93b |
| Vinst(TTM) | US$96.29m |
| Intäkter(TTM) | US$1.35b |
51.1x
P/E-förhållande3.6x
P/S-förhållandeÄr HAE övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| HAE resultaträkning (TTM) | |
|---|---|
| Intäkter | US$1.35b |
| Kostnad för intäkter | US$549.85m |
| Bruttovinst | US$802.16m |
| Övriga kostnader | US$705.88m |
| Intäkter | US$96.29m |
Senast redovisade vinst
Jun 27, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 2.12 |
| Bruttomarginal | 59.33% |
| Nettovinstmarginal | 7.12% |
| Skuld/egenkapitalförhållande | 140.3% |
Hur har HAE utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/20 14:17 |
| Aktiekurs vid dagens slut | 2026/08/20 00:00 |
| Intäkter | 2026/06/27 |
| Årlig intjäning | 2026/03/28 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Haemonetics Corporation bevakas av 24 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |
| Raymond Myers | Benchmark Company |